You searched for Acalabrutinib - Page 4 of 25

ASH 2021: Matching-Adjusted Indirect Treatment Comparison (MAIC) of Acalabrutinib Alone or in Combination with Obinutuzumab Versus Ibrutinib or Venetoclax Plus Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

March 16, 2022

Acalabrutinib (A) and ibrutinib (I) are both highly effective Bruton tyrosine kinase (BTK) inhibitors approved for the treatment of chronic lymphocytic leukemia (CLL) and given as continuous treatments until disease progression or unacceptable toxicity.

Does acalabrutinib work in the birc3 mutation? Or is venetoclax obinutuzumab better?

January 17, 2022

Ask the Doctor Question: I have to start my first therapy soon and living in Germany. First diagnosis in 2015 and until now, watch and wait. ighv mutated, trisomie12, birc3 mutation.

Can acalabrutinib be taken in a different form – suppository, under the tongue, or some other way?

January 17, 2022

Ask the Pharmacist Question: What steps can I take to improve absorption of acalabrutinib. I had a total gastrectomy in 1974 and a Roux en Y in 2005, so my compromised

Are there any side effects of dysphasia or esophageal spasm when taking acalabrutinib?

January 12, 2022

Ask the Pharmacist Question: Are there any side effects of dysphasia or esophageal spasm when taking acalabrutinib? I began this treatment 9/1/2021 and these effects began 2-3 weeks ago. I have

ASH 2020: Dr. Davids Discusses Phase II AVO Study of Acalabrutinib + Venetoclax + Obinutuzumab for Chronic Lymphocytic Leukemia (CLL)

November 24, 2021

This video was recorded at the 62nd Annual Meeting of the American Society of Hematology, held virtually in December 2020. Dr. Davids specializes in CLL and serves on the CLL Society’s Medical Advisory Board.

Dr. Neil Kay and Dr. Sameer Parikh on Early-Stage Treatment with Acalabrutinib for Chronic Lymphocytic Leukemia (CLL)

October 28, 2021

In this interview, our own Dr. Brian Koffman spoke with Dr. Neil Kay, a Professor of Medicine and a hematologist at Mayo Clinic, and Dr. Sameer Parikh, a hematologist, an oncologist at the Mayo Clinic in Rochester, MN. They discussed why early-stage patients usually do not receive treatment and how that paradigm may be changing with the availability of new targeted therapies and better prognostic markers.

ASCO 2021: Dr. Matthew Davids on Acalabrutinib vs. Ibrutinib for Chronic Lymphocytic Leukemia (CLL)

October 8, 2021

At the annual meeting of the American Society of Clinical Oncology (ASCO) 2021, our own Dr. Brian Koffman interviewed Dr. Matthew Davids, Associate Director of the Center for Chronic Lymphocytic Leukemia (CLL) at Dana-Farber Cancer Institute in Boston, MA. They discussed new data from the ELEVATE R/R study, which is comparing acalabrutinib with ibrutinib head-to-head in high-risk patients with relapsed/refractory CLL and del(17p) or del(11q).

ASCO 2021 Top Pick #12: Acalabrutinib ± Obinutuzumab Versus Obinutuzumab + Chlorambucil in Treatment-Naïve Chronic Lymphocytic Leukemia: ELEVATE-TN Four-Year Follow Up

October 4, 2021

While hardly groundbreaking, the four-year follow-up data of the ELEVATE-TN trial affirms our confidence that acalabrutinib is a strong choice for frontline therapy in CLL.

ASCO 2021 Top Pick #1: First Results of a Head-To-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia Patients

October 4, 2021

Does the increased selectivity of the Bruton tyrosine kinase inhibitor (BTKi) acalabrutinib (Aca) compared to ibrutinib (Ib) improve tolerability while maintaining efficacy?

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Search Results for: Acalabrutinib – Page 4

ASH 2021: Matching-Adjusted Indirect Treatment Comparison (MAIC) of Acalabrutinib Alone or in Combination with Obinutuzumab Versus Ibrutinib or Venetoclax Plus Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

Does acalabrutinib work in the birc3 mutation? Or is venetoclax obinutuzumab better?

Can acalabrutinib be taken in a different form – suppository, under the tongue, or some other way?

Are there any side effects of dysphasia or esophageal spasm when taking acalabrutinib?

ASH 2020: Dr. Davids Discusses Phase II AVO Study of Acalabrutinib + Venetoclax + Obinutuzumab for Chronic Lymphocytic Leukemia (CLL)

Dr. Neil Kay and Dr. Sameer Parikh on Early-Stage Treatment with Acalabrutinib for Chronic Lymphocytic Leukemia (CLL)

ASCO 2021: Dr. Matthew Davids on Acalabrutinib vs. Ibrutinib for Chronic Lymphocytic Leukemia (CLL)

ASCO 2021 Top Pick #12: Acalabrutinib ± Obinutuzumab Versus Obinutuzumab + Chlorambucil in Treatment-Naïve Chronic Lymphocytic Leukemia: ELEVATE-TN Four-Year Follow Up

ASCO 2021 Top Pick #1: First Results of a Head-To-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia Patients

Didn't find what you where looking for?

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT CLL SOCIETY

CONTACT